SV Life Sciences

Biotech firm Thesan Pharmaceuticals closes $49M in Series B round

Thesan Pharmaceuticals, a biotech firm that develops therapies for skin conditions, raised $49 million for its Series B round led by existing investor Novo Ventures and joined in by SV Life Sciences, Lundbeckfond Ventures and Novartis Venture Fund.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics